JP7479635B2 - γδＴ細胞の製造方法 - Google Patents

γδＴ細胞の製造方法 Download PDF

Info

Publication number
JP7479635B2
JP7479635B2 JP2020530276A JP2020530276A JP7479635B2 JP 7479635 B2 JP7479635 B2 JP 7479635B2 JP 2020530276 A JP2020530276 A JP 2020530276A JP 2020530276 A JP2020530276 A JP 2020530276A JP 7479635 B2 JP7479635 B2 JP 7479635B2
Authority
JP
Japan
Prior art keywords
cells
cell
medium
tcr
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530276A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020013315A1 (ja
Inventor
新 金子
翔一 入口
樹 上田
義明 葛西
哲 林
和英 中山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Kyoto University NUC
Original Assignee
Takeda Pharmaceutical Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Kyoto University NUC filed Critical Takeda Pharmaceutical Co Ltd
Publication of JPWO2020013315A1 publication Critical patent/JPWO2020013315A1/ja
Priority to JP2024065962A priority Critical patent/JP7817708B2/ja
Application granted granted Critical
Publication of JP7479635B2 publication Critical patent/JP7479635B2/ja
Priority to JP2025182692A priority patent/JP2026021431A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020530276A 2018-07-13 2019-07-12 γδＴ細胞の製造方法 Active JP7479635B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024065962A JP7817708B2 (ja) 2018-07-13 2024-04-16 γδＴ細胞の製造方法
JP2025182692A JP2026021431A (ja) 2018-07-13 2025-10-29 γδＴ細胞の製造方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018133727 2018-07-13
JP2018133727 2018-07-13
JP2019117891 2019-06-25
JP2019117891 2019-06-25
PCT/JP2019/027697 WO2020013315A1 (ja) 2018-07-13 2019-07-12 γδＴ細胞の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065962A Division JP7817708B2 (ja) 2018-07-13 2024-04-16 γδＴ細胞の製造方法

Publications (2)

Publication Number Publication Date
JPWO2020013315A1 JPWO2020013315A1 (ja) 2021-08-02
JP7479635B2 true JP7479635B2 (ja) 2024-05-09

Family

ID=69143058

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020530276A Active JP7479635B2 (ja) 2018-07-13 2019-07-12 γδＴ細胞の製造方法
JP2024065962A Active JP7817708B2 (ja) 2018-07-13 2024-04-16 γδＴ細胞の製造方法
JP2025182692A Pending JP2026021431A (ja) 2018-07-13 2025-10-29 γδＴ細胞の製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024065962A Active JP7817708B2 (ja) 2018-07-13 2024-04-16 γδＴ細胞の製造方法
JP2025182692A Pending JP2026021431A (ja) 2018-07-13 2025-10-29 γδＴ細胞の製造方法

Country Status (14)

Country Link
US (2) US12391739B2 (https=)
EP (1) EP3822342A4 (https=)
JP (3) JP7479635B2 (https=)
KR (1) KR20210030373A (https=)
CN (1) CN112513256A (https=)
AU (1) AU2019302207B2 (https=)
BR (1) BR112021000437A2 (https=)
CA (1) CA3106089A1 (https=)
CO (1) CO2021001064A2 (https=)
IL (1) IL280041A (https=)
MX (1) MX2021000459A (https=)
SG (1) SG11202100260QA (https=)
TW (1) TW202020145A (https=)
WO (1) WO2020013315A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
MX2021000459A (es) * 2018-07-13 2021-06-23 Univ Kyoto Metodo para producir celulas t gamma y delta.
CN109337870B (zh) 2018-12-24 2020-07-03 广东暨德康民生物科技有限责任公司 人Vγ9Vδ2T细胞扩增方法与培养基
MX2022006725A (es) * 2019-12-06 2022-08-22 Fate Therapeutics Inc Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
WO2021256522A1 (ja) 2020-06-17 2021-12-23 国立大学法人京都大学 キメラ抗原受容体発現免疫担当細胞
KR20230128324A (ko) * 2021-02-05 2023-09-04 고쿠리츠다이가쿠호진 고베다이가쿠 인공 다능성 줄기 세포 유래 γδ T 세포 및 그 제작방법
MX2023011927A (es) * 2021-04-07 2023-10-23 Century Therapeutics Inc Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
CN113583955A (zh) * 2021-08-24 2021-11-02 羽铂精制生物技术(成都)有限公司 一种因子法扩增t细胞的培养基及培养方法
US20230124097A1 (en) * 2021-10-14 2023-04-20 Appia Bio, Inc. Engineering stem cell t cells with multiple t cell receptors
KR20240101640A (ko) * 2021-11-12 2024-07-02 얀센 바이오테크 인코포레이티드 면역 세포의 향상된 확장 및 사용을 위한 재료 및 방법
EP4474476A4 (en) 2022-02-04 2026-02-18 Univ Kyoto T-LYMPHOCYTE PRODUCTION PROCESS
WO2023194911A1 (en) * 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Cells expressing an anti-mesothelin car
WO2023194915A1 (en) * 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Novel gene armoring
CN118931834B (zh) * 2024-03-07 2025-09-16 珠海善行免疫微生态产业研究院有限公司 一种人Vγ9Vδ2T细胞扩增培养基及其扩增培养方法
CN119530215A (zh) * 2024-11-27 2025-02-28 珠海医米诺赛医学检验有限公司 一种血液处理液及利用该处理液进行染色体核型分析的方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010017134A (ja) 2008-07-10 2010-01-28 Hyogo College Of Medicine Ｖγ９Ｖδ２Ｔ細胞の増殖剤、活性化Ｖγ９Ｖδ２Ｔ細胞の製造方法およびこれらの利用
JP2012528599A (ja) 2009-06-05 2012-11-15 セルラー ダイナミクス インターナショナル， インコーポレイテッド リプログラミングｔ細胞および造血細胞
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016010155A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
WO2016076415A1 (ja) 2014-11-13 2016-05-19 国立大学法人京都大学 多能性幹細胞からｔ細胞への誘導方法
WO2017075389A1 (en) 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
JP2017535284A (ja) 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
WO2018143243A1 (ja) 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JP2020506713A (ja) 2017-02-07 2020-03-05 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ATE449162T1 (de) 2000-04-03 2009-12-15 Therapure Biopharma Inc Herstellung von tcr gamma delta t-zellen
US9453219B2 (en) 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
JPWO2006006720A1 (ja) 2004-07-13 2008-05-01 株式会社メディネット γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
US9051391B2 (en) 2007-06-11 2015-06-09 Takara Bio Inc. Method for expression of specific gene
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
AU2008297011B2 (en) 2007-08-31 2014-06-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
JP5558097B2 (ja) 2007-12-10 2014-07-23 国立大学法人京都大学 効率的な核初期化方法
US20100330063A1 (en) 2007-12-17 2010-12-30 Gliamed, Inc. Stem-like cells, method for de-differentiating mammalian somatic cells into stem-like cells, and method for differentiating stem-like cells
WO2009091659A2 (en) 2008-01-16 2009-07-23 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
EP2250252A2 (en) 2008-02-11 2010-11-17 Cambridge Enterprise Limited Improved reprogramming of mammalian cells, and the cells obtained
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
US20110014164A1 (en) 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009114949A1 (en) 2008-03-20 2009-09-24 UNIVERSITé LAVAL Methods for deprogramming somatic cells and uses thereof
AU2009234424A1 (en) 2008-04-07 2009-10-15 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator
CA2695590C (en) 2008-06-27 2018-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2313494A2 (en) 2008-07-14 2011-04-27 Oklahoma Medical Research Foundation Production of pluripotent cells through inhibition of bright/arid3a function
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
WO2010042800A1 (en) 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
WO2010050626A1 (en) 2008-10-30 2010-05-06 Kyoto University Method for producing induced pluripotent stem cells
WO2010056831A2 (en) 2008-11-12 2010-05-20 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
US9045737B2 (en) 2008-12-13 2015-06-02 Dnamicroarray, Inc. Artificial three-dimensional microenvironment niche culture
JP5553289B2 (ja) 2009-02-27 2014-07-16 国立大学法人京都大学 新規核初期化物質
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
WO2010111422A2 (en) 2009-03-25 2010-09-30 The Salk Institute For Biological Studies Induced pluripotent stem cell generation using two factors and p53 inactivation
WO2010111409A2 (en) 2009-03-25 2010-09-30 The Salk Institute For Biological Studies Pluripotent stem cells
US8852940B2 (en) 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
US20110088107A1 (en) 2009-04-24 2011-04-14 Yaqub Hanna Compositions and methods for deriving or culturing pluripotent cells
WO2010147395A2 (en) 2009-06-16 2010-12-23 Korea Research Institute Of Bioscience And Biotechnology Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
CN104053769A (zh) 2011-11-21 2014-09-17 大学健康网络 造血祖细胞群体和富集其干细胞的方法
KR102654784B1 (ko) * 2014-07-18 2024-04-04 사이아스 가부시키가이샤 다능성 줄기세포로부터 세포-기반 면역요법용 t 세포를 유도하는 방법
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
EP4295914A3 (en) 2015-09-03 2024-04-10 The UAB Research Foundation Genetically-engineered drug resistant t cells and methods of using the same
JP7017008B2 (ja) * 2015-10-15 2022-02-08 国立大学法人京都大学 多能性幹細胞からｃｄ４陽性ｔ細胞を製造する方法
ES2886631T3 (es) * 2016-04-15 2021-12-20 Univ Kyoto Método para inducir células T positivas para CD8 específicas de antígeno
EP3476934A4 (en) * 2016-06-23 2020-02-26 Kyoto University METHOD FOR PRODUCING CD4 / CD8 POSITIVE DUAL T CELLS
EP3572502B1 (en) 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
JP2018133727A (ja) 2017-02-16 2018-08-23 富士通株式会社 無線通信システム、無線通信装置、及びビームパターン決定方法
EP3597734A4 (en) * 2017-03-14 2021-03-03 Kyoto University METHOD FOR PRODUCING HELPER T-CELLS FROM PLURIPOTENT STEM CELLS
JP7109916B2 (ja) 2017-12-27 2022-08-01 株式会社ディスコ 分割装置
MX2021000459A (es) 2018-07-13 2021-06-23 Univ Kyoto Metodo para producir celulas t gamma y delta.
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
JP7723935B2 (ja) * 2019-11-01 2025-08-15 国立大学法人京都大学 Ｔ細胞の製造方法
AU2020393334A1 (en) * 2019-11-25 2022-06-16 Kyoto University T-cell master cell bank
WO2022059780A1 (ja) * 2020-09-18 2022-03-24 サイアス株式会社 ｉＰＳ細胞を介する再生Ｔ細胞の製造方法
CA3193384A1 (en) * 2020-09-24 2022-03-31 Hiroshi Kawamoto Method for preparing effector cells with desired specificity
JPWO2022145490A1 (https=) * 2021-01-04 2022-07-07

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010017134A (ja) 2008-07-10 2010-01-28 Hyogo College Of Medicine Ｖγ９Ｖδ２Ｔ細胞の増殖剤、活性化Ｖγ９Ｖδ２Ｔ細胞の製造方法およびこれらの利用
JP2012528599A (ja) 2009-06-05 2012-11-15 セルラー ダイナミクス インターナショナル， インコーポレイテッド リプログラミングｔ細胞および造血細胞
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016010155A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
JP2017535284A (ja) 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
WO2016076415A1 (ja) 2014-11-13 2016-05-19 国立大学法人京都大学 多能性幹細胞からｔ細胞への誘導方法
WO2017075389A1 (en) 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
WO2018143243A1 (ja) 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JP2020506713A (ja) 2017-02-07 2020-03-05 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Cell Stem Cell，2018年12月，Vol.23，pp.850-858
Journal of Leukocyte Biology，Vol.96，2014年，pp.1165-1175
Nature Biotechnology，2013年，Vol.31, No.10，pp.928-933, ONLINE METHODS
PLOS ONE, 2014, Vol.9, No.5, e97335
Stem Cell Reports，2023年04月，Vol.18，pp.853-868
Stem Cells Translational Medicine，2017年11月，Vol.7，pp.34-44
Stem Cells，2015年，Vol.33，pp.3174-3180
WATANABE, D. et al.，Development of ipsc-based γδT-cell immunotherapy for digestive cancer，Gastroenterology，2017年04月，Vol.152, No.5, Supplement 1，p.S641，ISSN: 0016-5085, 全文
渡邉大輔 他，iPS細胞由来Vγ9Vδ2T細胞を用いる新規消化器がん治療法の開発，第24回日本消化器関連学会週間，2016年，消P-413
渡邉大輔 他，iPS細胞由来Vγ9Vδ2T細胞を用いる新規消化器がん治療法の開発，第24回日本消化器関連学会週間，2016年，消P-413，全文
青井貴之，同種iPS細胞由来γδT細胞を用いたがん免疫療法の可能性，医学のあゆみ，2017年12月，Vol.263, Nos.11,12，pp.915-919
青井貴之，同種iPS細胞由来γδT細胞を用いたがん免疫療法の可能性，医学のあゆみ，2017年12月，Vol.263, Nos.11,12，pp.915-919，ISSN: 0039-2359, 特にp.916左欄第２段落, p.917右欄第４段落, p.918右欄第２段落, 図１

Also Published As

Publication number Publication date
TW202020145A (zh) 2020-06-01
JP2026021431A (ja) 2026-02-10
CN112513256A (zh) 2021-03-16
MX2021000459A (es) 2021-06-23
AU2019302207B2 (en) 2025-11-20
SG11202100260QA (en) 2021-02-25
BR112021000437A2 (pt) 2021-04-06
US20250333470A1 (en) 2025-10-30
US12391739B2 (en) 2025-08-19
KR20210030373A (ko) 2021-03-17
US20210130777A1 (en) 2021-05-06
EP3822342A4 (en) 2022-08-03
IL280041A (en) 2021-03-01
WO2020013315A1 (ja) 2020-01-16
CA3106089A1 (en) 2020-01-16
CO2021001064A2 (es) 2021-02-08
AU2019302207A1 (en) 2021-03-04
JP2024096899A (ja) 2024-07-17
JPWO2020013315A1 (ja) 2021-08-02
JP7817708B2 (ja) 2026-02-19
EP3822342A1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
JP7817708B2 (ja) γδＴ細胞の製造方法
JP7678508B2 (ja) Ｃｄ３陽性細胞の製造方法
US20230000915A1 (en) T-cell master cell bank
HK40046047A (en) Method for producing gamma delta t cells
TW202609051A (zh) γδT細胞的製造方法
EA046950B1 (ru) СПОСОБ ПОЛУЧЕНИЯ γδT-КЛЕТОК
HK40113605A (en) Method for producing cd3-positive cell
HK40048467A (en) Method for producing cd3-positive cell
HK40048467B (en) Method for producing cd3-positive cell
HK40078413A (en) T-cell master cell bank
EA052927B1 (ru) Способ продуцирования cd3-позитивных клеток
EA048217B1 (ru) Способ продуцирования cd3-позитивных клеток

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240416

R150 Certificate of patent or registration of utility model

Ref document number: 7479635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150